top of page

Gary J. Bridger, PhD

Board Director

Dr. Bridger has over 30 years of industry experience in the biotech industry having worked on the research and investor side of the business as well as serving on numerous boards.  He is currently an independent board director of two publicly traded companies, Liminal BioSciences, Inc. and X4 Pharmaceuticals, Inc. where he has served since 2018 and 2019, respectively. Previously he also served on the board of directors of Aquinox Pharmaceuticals for 4 years.  From a research perspective, he is currently acting interim CSO of Liminal Biosciences and previously served as a consultant and Executive Vice President of Research and Development at Xenon Pharmaceuticals. Earlier in his career, Dr. Bridger co-founded AnorMED Inc., a biopharmaceutical company, and was the Vice President of Research and Development and Chief Scientific Officer until its acquisition by Genzyme in 2006. After the acquisition Dr. Bridger served as Senior Vice President of Research and Development of Genzyme Corporation, a biotechnology company, which was later acquired by Sanofi, S.A.  Dr. Bridger also spent time working in venture capital where he was a venture partner at Venture West Capital Management from 2010 to 2012 and subsequently joined Five Corners Capital as a Managing Director from 2013 to 2015. Dr. Bridger holds a Ph.D. in Organic Chemistry and a BS (Hons) from the University of Manchester Institute of Science and Technology.

bottom of page